A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults

A Phase I, First-Time-in Human (FTiH), Open-label, Dose Escalation, Non-randomized Study to Assess Safety, Reactogenicity and Immune Response of a CoV-2 SAM (LNP) Vaccine When Administered Intramuscularly on a 0, 1 Month Schedule in Healthy Adults 18 to 50 Years of Age

The purpose of this study is to assess the safety, reactogenicity and immune response of a self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike antigen (CoV-2 SAM [LNP] vaccine) in ascending doses when administered intramuscularly (IM) on a 0,1-month schedule to healthy adults 18 to 50 years of age. There will be no administration of escalated doses of the study vaccine.

Study Overview

• Status: Completed
• Conditions: Virus Diseases
• Intervention / Treatment: Biological: 1 µg CoV2 SAM (LNP)

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • New York
    • Rochester, New York, United States, 14609
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
• Written or thumb printed informed consent obtained from the participant prior to performance of any study specific procedure.
• Healthy participants as established by medical history and clinical examination before entering into the study.
• A male or female between, and including, 18 and 50 years of age at the time of first study intervention administration.
• Body Mass Index>18 Kg/m^2 and <30 Kg/m^2.
• Participants with following hematological/biochemical parameters:
• White Blood Cells within the study designated laboratory normal range. Participants with FDA toxicity grade 1 differential cell counts and considered not clinically significant may be enrolled at the discretion of the investigator, and with the review and approval of the medical monitor.
• Platelets = 125,000 - 500,000 cells/mm^3.
• Hemoglobin within normal range of the study designated laboratory.
• Alanine aminotransferase within the study designated laboratory normal range.
• Aspartate aminotransferase within the study designated laboratory normal range Total bilirubin within the study designated laboratory normal range.
• Alkaline phosphatase within the study designated laboratory normal range.
• Blood urea nitrogen within the study designated laboratory normal range.
• Serum creatinine less than or equal to 1.1 times study designated laboratory's upper limit of normal.
• Seronegative for hepatitis B surface antigen, hepatitis C virus antibodies, or human immunodeficiency virus antibodies.
• Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.
• Female participants of childbearing potential may be enrolled in the study, if the participant:
• has practiced adequate contraception for 1 month prior to study intervention administration, and,
• has a negative pregnancy test on the day of study intervention administration, and,
• has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the study intervention administration series.

Exclusion Criteria:

Medical conditions

• Individuals with signs and symptoms consistent with COVID-19, according to CDC guidelines and following clinical judgement.
• Nasal and/or oral swab positive for SARS-CoV-2 by RT-PCR within the last 30 days, unless participant has had a subsequent negative swab and is asymptomatic.
• Close contact (within 30 days prior to study intervention administration) with anyone known to have SARS-CoV-2 infection.
• Individuals currently working in occupations with high risk of exposure to SARS-CoV-2 (e.g., healthcare workers, emergency response personnel).
• Any confirmed or suspected immunosuppressive/immunodeficient condition based on medical history and physical examination.
• Family history of congenital/hereditary immunodeficiency.
• History of or current autoimmune disease.
• History of any reaction/hypersensitivity likely to be exacerbated by any components of the study intervention.
• History of hypersensitivity/severe allergic reaction to any previous licensed/unlicensed vaccine.
• Lymphoproliferative disorder/malignancy within previous 5 years (excluding effectively treated non-melanotic skin cancer).
• History of recurrent anemia within the last 6 months.
• Hypersensitivity to latex.
• Any acute/chronic, clinically significant disease The following conditions will be exclusionary:
• Diabetes mellitus (type I or II), with exception of gestational diabetes.
• Respiratory disease such as:
• Chronic Pulmonary diseases,
• Bronchopulmonary dysplasia,
• Uncontrolled asthma/asthma necessitating treatment with chronic systemic/inhaled glucocorticoids.
• Significant and/or uncontrolled psychiatric illness:
• hospitalization for psychiatric illness, history of suicide attempts/confinement for danger to self/others within 5 years,
• clinically significant depression.
• Major neurological disease including:
• seizure or adulthood epilepsy (note: history of febrile convulsion in childhood is not exclusionary),
• myasthenia gravis,
• history of repetitive migraine mal/status migrainosus.
• Significant cardiovascular disease, including:
• Uncontrolled arterial hypertension,
• Congenital heart disease,
• Previous myocardial infarction,
• Valvular heart disease or history of rheumatic fever,
• Previous bacterial endocarditis,
• History of cardiac surgery,
• Personal/ family history of cardiomyopathy/sudden adult death.
• Asplenia, functional asplenia/any condition resulting in the absence/removal of the spleen.
• Hereditary angioedema, acquired angioedema/ idiopathic forms of angioedema.
• History of, or concurrent, autoimmune thyroid disease regardless of treatment and thyroid status as well as any uncontrolled thyroid disease.
• Idiopathic urticaria within the past year.
• Any other significant uncontrolled medical illness within 3 months prior to study intervention administration.
• Acute illness and/or fever at the time of screening. Participants with acute illness and/ or fever at the time of screening may be re screened later.
• Participants with a minor illness without fever may be enrolled.
• Any other clinical condition that might pose additional risk to the participant due to participation in the study.

Prior/Concomitant therapy

• Use of any investigational or non-registered product other than the study intervention(s) during the period beginning 45 days before the first dose (Day -45 to Day 1), or their planned use during the study.
• Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the vaccination and ending 30 days after, with the exception of any licensed influenza vaccine which may be administered >15 days before/after vaccination.
• Planned administration/administration of an Emergency Use Authorization vaccine against SARS-CoV-2 in the period starting prior to the first dose of study intervention and ending 15 days after the second dose of study intervention
• Administration of long-acting immune-modifying drugs at any time during the study
• Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the administration of the first dose until study end.
• Chronic administration of immunosuppressants/other immune-modifying drugs during the period starting 6 months prior to the first dose. For corticosteroids, this will mean prednisone equivalent >10 mg/day. Topical steroids are allowed.

Prior/Concurrent clinical study experience

• Receipt of any other SARS-CoV-2 or other experimental coronavirus vaccine at any time prior to or during the study
• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been/will be exposed to an investigational/a non-investigational intervention

Other exclusions

• Pregnant/lactating female
• Female planning to become pregnant/planning to discontinue contraceptive precautions
• Alcohol and/or drug abuse.
• Current/history of chronic tobacco/marijuana smoking/vaping.
• Participants with extensive tattoos covering deltoid region on both the arms that would preclude the assessment of local reactogenicity.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1 µg CoV2 SAM (LNP) Group; Participants aged 18-50 years, allocated in the 1 µg COV2 SAM (LNP) Group receive 2 doses of 1 µg CoV2 SAM (LNP) vaccine 30 days apart, at day 1 and day 31 and are followed up until the study end.	Biological: 1 µg CoV2 SAM (LNP); 2 doses of 1 µg CoV2 SAM (LNP) vaccine in 0,1-month schedule, administered IM in the deltoid of the non-dominant arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with at least 1 solicited administration site event during 7-day follow-up period after first vaccination (first vaccination occurs on Day 1)	The solicited administration site events are pain, redness and swelling.	7-day follow-up period after first vaccination (from Day 1 to Day 7)
Number of participants with at least 1 solicited administration site event during 7-day follow-up period after second vaccination (second vaccination occurs on Day 31)	The solicited administration site events are pain, redness and swelling.	7-day follow-up period after second vaccination (from Day 31 to Day 37)
Number of participants with at least 1 solicited systemic event during 7-day follow-up period after first vaccination (first vaccination occurs on Day 1)	The solicited systemic events are fatigue, fever, nausea, vomiting, diarrhea, abdominal pain, headache, myalgia and arthralgia.	7-day follow-up period after first vaccination (from Day 1 to Day 7)
Number of participants with at least 1 solicited systemic event during 7-day follow-up period after second vaccination (second vaccination occurs on Day 31)	The solicited systemic events are fatigue, fever, nausea, vomiting, diarrhea, abdominal pain, headache, myalgia and arthralgia.	7-day follow-up period after second vaccination (from Day 31 to Day 37)
Number of participants with any unsolicited adverse event (AE) during 30-day follow-up period after first vaccination (first vaccination occurs on Day 1)	An unsolicited AE is an AE that was not included in a list of solicited events using a Participant Diary. Unsolicited events must have been spontaneously communicated by a participant who has signed the informed consent. Unsolicited AEs include both serious and non-serious AEs.	30-day follow-up period after first vaccination (from Day 1 to Day 30)
Number of participants with any unsolicited AE during 30-day follow-up period after second vaccination (second vaccination occurs on Day 31)	An unsolicited AE is an AE that was not included in a list of solicited events using a Participant Diary. Unsolicited events must have been spontaneously communicated by a participant who has signed the informed consent. Unsolicited AEs include both serious and non-serious AEs.	30-day follow-up period after second vaccination (from Day 31 to Day 60)
Number of participants with any hematological and biochemical laboratory abnormality at screening	Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Hematology and biochemistry results below or above the laboratory normal ranges were evaluated for the following parameters: Hematology: platelet count, red blood cell (RBC) count, hemoglobin, white blood cell (WBC) count with differential neutrophils, lymphocytes and eosinophils. Biochemistry: blood urea nitrogen (BUN), creatinine, liver function tests - alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin.	At Screening
Number of participants with any hematological and biochemical laboratory abnormality at Day 1	Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Hematology and biochemistry results below or above the laboratory normal ranges were evaluated for the following parameters: Hematology: platelet count, red blood cell (RBC) count, hemoglobin, white blood cell (WBC) count with differential neutrophils, lymphocytes and eosinophils. Biochemistry: blood urea nitrogen (BUN), creatinine, liver function tests - alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin.	At Day 1
Number of participants with any hematological and biochemical laboratory abnormality at Day 2	Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Hematology and biochemistry results below or above the laboratory normal ranges were evaluated for the following parameters: Hematology: platelet count, red blood cell (RBC) count, hemoglobin, white blood cell (WBC) count with differential neutrophils, lymphocytes and eosinophils. Biochemistry: blood urea nitrogen (BUN), creatinine, liver function tests - alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin.	At Day 2
Number of participants with any hematological and biochemical laboratory abnormality at Day 8	Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Hematology and biochemistry results below or above the laboratory normal ranges were evaluated for the following parameters: Hematology: platelet count, red blood cell (RBC) count, hemoglobin, white blood cell (WBC) count with differential neutrophils, lymphocytes and eosinophils. Biochemistry: blood urea nitrogen (BUN), creatinine, liver function tests - alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin.	At Day 8
Number of participants with any hematological and biochemical laboratory abnormality at Day 31	Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Hematology and biochemistry results below or above the laboratory normal ranges were evaluated for the following parameters: Hematology: platelet count, red blood cell (RBC) count, hemoglobin, white blood cell (WBC) count with differential neutrophils, lymphocytes and eosinophils. Biochemistry: blood urea nitrogen (BUN), creatinine, liver function tests - alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin.	At Day 31
Number of participants with any hematological and biochemical laboratory abnormality at Day 32	Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Hematology and biochemistry results below or above the laboratory normal ranges were evaluated for the following parameters: Hematology: platelet count, red blood cell (RBC) count, hemoglobin, white blood cell (WBC) count with differential neutrophils, lymphocytes and eosinophils. Biochemistry: blood urea nitrogen (BUN), creatinine, liver function tests - alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin.	At Day 32
Number of participants with any hematological and biochemical laboratory abnormality at Day 38	Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Hematology and biochemistry results below or above the laboratory normal ranges were evaluated for the following parameters: Hematology: platelet count, red blood cell (RBC) count, hemoglobin, white blood cell (WBC) count with differential neutrophils, lymphocytes and eosinophils. Biochemistry: blood urea nitrogen (BUN), creatinine, liver function tests - alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin.	At Day 38
Number of participants with at least 1 medically attended AE (MAE) from first administered dose up to 30 days after last dose (second vaccination occurs on Day 31)	A MAE is an AE for which the participants received medical attention defined as hospitalization, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits.	From Day 1 to Day 60
Number of participants with at least 1 serious adverse event (SAE) from first administered dose up to 30 days after last dose (second vaccination occurs on Day 31)	An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study patient.	From Day 1 to Day 60
Number of participants with at least 1 adverse event of special interest (AESI) from first administered dose up to 30 days after last dose (second vaccination occurs on Day 31)	Potential immune-mediated diseases (pIMDs) are a subset of AESIs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Other AESIs are COVID-19 cases (any suspected, probable or confirmed case of COVID-19 should be reported by the principal investigator as AESI, as defined by World Health Organization).	From Day 1 to Day 60

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with at least 1 MAE from first administered dose up to study conclusion	A MAE is an AE for which the participants received medical attention defined as hospitalization, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits.	From Day 1 to Day 391
Number of participants with at least 1 SAE from first administered dose up to study conclusion	An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study patient.	From Day 1 to Day 391
Number of participants with at least 1 AESI from first administered dose up to study conclusion	pIMDs are a subset of AESIs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Other AESIs are COVID-19 cases (any suspected, probable or confirmed case of COVID-19 should be reported by the principal investigator as AESI, as defined by World Health Organization).	From Day 1 to Day 391
Humoral immune response in terms of SARS-CoV-2 Anti-Spike immunoglobulin G (IgG) antibody geometric mean concentrations (GMCs) at pre-vaccination, first dose (first vaccination occurs on Day 1)	Anti-Spike IgG antibodies GMCs are performed by enzyme-linked immunosorbent assay (ELISA).	At Day 1
Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at pre-vaccination, second dose (second vaccination occurs on Day 31)	Anti-Spike IgG antibody GMCs are performed by ELISA.	At Day 31
Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at 1 month after last dose (second vaccination occurs on Day 31)	Anti-Spike IgG antibody GMCs are performed by ELISA.	At Day 61
Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at pre-vaccination, first dose (first vaccination occurs on Day 1)	Anti-Nucleocapsid IgG antibody GMCs are performed by ELISA.	At Day 1
Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at pre-vaccination, second dose (second vaccination occurs on Day 31)	Anti-Nucleocapsid IgG antibody GMCs are performed by ELISA.	At Day 31
Humoral immune response in terms of Anti-Nucleocapsid IgG antibody GMCs at 1 month after last dose (second vaccination occurs on Day 31)	Anti-Nucleocapsid IgG antibody GMCs are performed by ELISA.	At Day 61
Humoral immune response in terms of SARS-CoV-2 neutralizing antibody Geometric Mean Titers (GMTs) at pre-vaccination, first dose (first vaccination occurs on Day 1)	SARS-CoV-2 neutralizing antibody GMTs are performed by neutralization assay.	At Day 1
Humoral immune response in terms of SARS-CoV-2 neutralizing antibody GMTs at pre-vaccination, second dose (second vaccination occurs on Day 31)	SARS-CoV-2 neutralizing antibody GMTs are performed by neutralization assay.	At Day 31
Humoral immune response in terms of SARS-CoV-2 neutralizing antibody GMTs at 1 month after last dose (second vaccination occurs on Day 31)	SARS-CoV-2 neutralizing antibody GMTs are performed by neutralization assay.	At Day 61
Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at Day 8	Anti-Spike IgG antibody GMCs are performed by ELISA.	At Day 8
Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at Day 15	Anti-Spike IgG antibody GMCs are performed by ELISA.	At Day 15
Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at Day 38	Anti-Spike IgG antibody GMCs are performed by ELISA.	At Day 38
Humoral immune response in terms of SARS-CoV-2 Anti-Spike IgG antibody GMCs at Day 45	Anti-Spike IgG antibody GMCs are performed by ELISA.	At Day 45
Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at Day 8	Anti-Nucleocapsid IgG antibody GMCs are performed by ELISA.	At Day 8
Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at Day 15	Anti-Nucleocapsid IgG antibody GMCs are performed by ELISA.	At Day 15
Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at Day 38	Anti-Nucleocapsid IgG antibody GMCs are performed by ELISA.	At Day 38
Humoral immune response in terms of SARS-CoV-2 Anti-Nucleocapsid IgG antibody GMCs at Day 45	Anti-Nucleocapsid IgG antibody GMCs are performed by ELISA.	At Day 45
Cell mediated immune (CMI) response in terms of frequency of SARS-CoV-2 Spike-specific Cluster of Differentiation (CD) 4+ and CD8+ T-cells secreting at least 2 markers including one cytokine at pre-vaccination, first dose	SARS-CoV-2 Spike-specific cytokine producing CD4+ and CD8+ T-cell responses is measured by flow cytometry using intracellular cytokine staining (ICS).	At Day 1
CMI response in terms of frequency of SARS-CoV-2 Spike-specific CD4+ and CD8+ T-cells secreting at least 2 markers including one cytokine at pre-vaccination, second dose	SARS-CoV-2 Spike-specific cytokine producing CD4+ and CD8+ T-cell responses is measured by flow cytometry using ICS.	At Day 31
CMI response in terms of frequency of SARS-CoV-2 Spike-specific CD4+ and CD8+ T-cells secreting at least 2 markers including one cytokine at Day 61	SARS-CoV-2 Spike-specific cytokine producing CD4+ and CD8+ T-cell responses is measured by flow cytometry using ICS.	At Day 61

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• Maruggi G, Mallett CP, Westerbeck JW, Chen T, Lofano G, Friedrich K, Qu L, Sun JT, McAuliffe J, Kanitkar A, Arrildt KT, Wang KF, McBee I, McCoy D, Terry R, Rowles A, Abrahim MA, Ringenberg MA, Gains MJ, Spickler C, Xie X, Zou J, Shi PY, Dutt T, Henao-Tamayo M, Ragan I, Bowen RA, Johnson R, Nuti S, Luisi K, Ulmer JB, Steff AM, Jalah R, Bertholet S, Stokes AH, Yu D. A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models. Mol Ther. 2022 May 4;30(5):1897-1912. doi: 10.1016/j.ymthe.2022.01.001. Epub 2022 Jan 3.

Study record dates

Study Major Dates

• Study Start (Actual): February 15, 2021
• Primary Completion (Actual): June 4, 2021
• Study Completion (Actual): April 19, 2022

Study Registration Dates

• First Submitted: February 8, 2021
• First Submitted That Met QC Criteria: February 16, 2021
• First Posted (Actual): February 17, 2021

Study Record Updates

• Last Update Posted (Actual): January 18, 2024
• Last Update Submitted That Met QC Criteria: January 17, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Virus Diseases
• Other Study ID Numbers: 214525

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
• IPD Sharing Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
• IPD Sharing Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No